Several days ago, Ocugen was an early-stage biotech company focusing on gene therapy to cure eye diseases. And then everything changed. All of a sudden, investors began piling into the shares, and the company joined the center stage of the stock market with the likes of Pfizer and Moderna.
Trending:
Can COVID vaccine latecomer Ocugen beat Pfizer and Moderna?